95 related articles for article (PubMed ID: 9645342)
1. Neuronal src and trk a protooncogene expression in neuroblastomas and patient prognosis.
Matsunaga T; Shirasawa H; Enomoto H; Yoshida H; Iwai J; Tanabe M; Kawamura K; Etoh T; Ohnuma N
Int J Cancer; 1998 Jun; 79(3):226-31. PubMed ID: 9645342
[TBL] [Abstract][Full Text] [Related]
2. Expression of neuronal src mRNA as a favorable marker and inverse correlation to N-myc gene amplification in human neuroblastomas.
Matsunaga T; Shirasawa H; Tanabe M; Ohnuma N; Kawamura K; Etoh T; Takahashi H; Simizu B
Int J Cancer; 1994 Sep; 58(6):793-8. PubMed ID: 7523310
[TBL] [Abstract][Full Text] [Related]
3. trk A gene expression in neuroblastoma. The clinical significance of an immunohistochemical study.
Tanaka T; Hiyama E; Sugimoto T; Sawada T; Tanabe M; Ida N
Cancer; 1995 Sep; 76(6):1086-95. PubMed ID: 8625212
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of N-myc messenger RNA in neuroblastomas found by mass screening.
Matsunaga T; Shirasawa H; Hishiki T; Yoshida H; Kouchi K; Ohtsuka Y; Kawamura K; Etoh T; Ohnuma N
Clin Cancer Res; 2000 Aug; 6(8):3199-204. PubMed ID: 10955804
[TBL] [Abstract][Full Text] [Related]
5. Expression of N-myc and c-src protooncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas.
Matsunaga T; Takahashi H; Ohnuma N; Tanabe M; Yoshida H; Iwai J; Shirasawa H; Simizu B
Cancer Res; 1991 Jun; 51(12):3148-52. PubMed ID: 2039993
[TBL] [Abstract][Full Text] [Related]
6. Expression of alternatively spliced src messenger RNAs related to neuronal differentiation in human neuroblastomas.
Matsunaga T; Shirasawa H; Tanabe M; Ohnuma N; Takahashi H; Simizu B
Cancer Res; 1993 Jul; 53(13):3179-85. PubMed ID: 8319227
[TBL] [Abstract][Full Text] [Related]
7. Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening.
Tanaka T; Sugimoto T; Sawada T
Cancer; 1998 Oct; 83(8):1626-33. PubMed ID: 9781958
[TBL] [Abstract][Full Text] [Related]
8. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.
Nakagawara A; Arima-Nakagawara M; Scavarda NJ; Azar CG; Cantor AB; Brodeur GM
N Engl J Med; 1993 Mar; 328(12):847-54. PubMed ID: 8441429
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis.
Kogner P; Barbany G; Dominici C; Castello MA; Raschellá G; Persson H
Cancer Res; 1993 May; 53(9):2044-50. PubMed ID: 8481906
[TBL] [Abstract][Full Text] [Related]
10. Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma.
Svensson T; Rydén M; Schilling FH; Dominici C; Sehgal R; Ibáñez CF; Kogner P
Eur J Cancer; 1997 Oct; 33(12):2058-63. PubMed ID: 9580079
[TBL] [Abstract][Full Text] [Related]
11. Trk mRNA and low affinity nerve growth factor receptor mRNA expression and triploid DNA content in favorable neuroblastoma tumors.
Kogner P; Barbany G; Björk O; Castello MA; Donfrancesco A; Falkmer UG; Hedborg F; Kouvidou H; Persson H; Raschella G
Prog Clin Biol Res; 1994; 385():137-45. PubMed ID: 7972205
[TBL] [Abstract][Full Text] [Related]
12. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas.
Nakagawara A; Arima M; Azar CG; Scavarda NJ; Brodeur GM
Cancer Res; 1992 Mar; 52(5):1364-8. PubMed ID: 1737399
[TBL] [Abstract][Full Text] [Related]
13. Expression and function of Trk-C in favourable human neuroblastomas.
Yamashiro DJ; Liu XG; Lee CP; Nakagawara A; Ikegaki N; McGregor LM; Baylin SB; Brodeur GM
Eur J Cancer; 1997 Oct; 33(12):2054-7. PubMed ID: 9516852
[TBL] [Abstract][Full Text] [Related]
14. Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?--An overview.
Tsuchida Y; Hemmi H; Inoue A; Obana K; Yang HW; Hayashi Y; Kanda N; Shimatake H
Tumour Biol; 1996; 17(2):65-74. PubMed ID: 8658015
[TBL] [Abstract][Full Text] [Related]
15. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas.
Suzuki T; Bogenmann E; Shimada H; Stram D; Seeger RC
J Natl Cancer Inst; 1993 Mar; 85(5):377-84. PubMed ID: 8433391
[TBL] [Abstract][Full Text] [Related]
16. Shc family expression in neuroblastoma: high expression of shcC is associated with a poor prognosis in advanced neuroblastoma.
Terui E; Matsunaga T; Yoshida H; Kouchi K; Kuroda H; Hishiki T; Saito T; Yamada S; Shirasawa H; Ohnuma N
Clin Cancer Res; 2005 May; 11(9):3280-7. PubMed ID: 15867224
[TBL] [Abstract][Full Text] [Related]
17. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
18. The expression profile of alternatively spliced neuronal c-src RNA distinguishes between human tumours of the sympatho-adrenal lineage.
Ortoft E; Bjelfman C; Hedborg F; Grimelius L; Påhlman S
Int J Cancer; 1995 Jan; 60(1):38-44. PubMed ID: 7529211
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of pleiotrophin and midkine in advanced neuroblastomas.
Nakagawara A; Milbrandt J; Muramatsu T; Deuel TF; Zhao H; Cnaan A; Brodeur GM
Cancer Res; 1995 Apr; 55(8):1792-7. PubMed ID: 7712489
[TBL] [Abstract][Full Text] [Related]
20. Biochemical evidence for a mature phenotype in morphologically poorly differentiated neuroblastomas with a favourable outcome.
Hedborg F; Bjelfman C; Sparén P; Sandstedt B; Påhlman S
Eur J Cancer; 1995; 31A(4):435-43. PubMed ID: 7576941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
